Key Takeaways
- • CREATE Medicines closed a $122 million Series B funding round co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and existing syndicate members.
- • The Cambridge-based clinical-stage biotech company has developed a proprietary mRNA-LNP platform designed to directly engineer T cells, NK cells, and myeloid cells in vivo for scalable, repeat-dose immunotherapies.
- • CREATE's pipeline focuses on in vivo CAR therapies spanning both autoimmune diseases and oncology indications, positioning the company at the intersection of two large therapeutic markets.
- • The funding validates investor confidence in CREATE's in vivo immune programming approach, which differentiates from traditional ex vivo CAR-T therapies by engineering immune cells directly within the patient's body.
Summary
CREATE Medicines announced the close of its $122 million Series B financing round, strengthening the company's position in the competitive immunotherapy sector. The round was co-led by three venture firms—Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners—alongside participation from Alexandria Venture Investments and other members of CREATE's existing investor base. This syndicate composition signals broad institutional backing and confidence in the company's technology trajectory.
The Cambridge-based biotechnology firm specializes in in vivo immune programming, a therapeutic approach that distinguishes itself from conventional CAR-T cell therapies. CREATE's proprietary mRNA-lipid nanoparticle (mRNA-LNP) platform enables direct engineering of immune cell populations—specifically T cells, natural killer cells, and myeloid cells—within the patient's body rather than through ex vivo manufacturing and reinfusion. This approach aims to address scalability and cost challenges that have constrained the broader CAR-T market, while enabling repeat-dosing protocols that traditional cell therapies cannot support.
The company's clinical pipeline encompasses in vivo CAR therapies targeting both autoimmune diseases and cancer indications. This dual-indication strategy expands CREATE's addressable market beyond oncology, which has dominated CAR-T development to date, and offers investors exposure to two substantial therapeutic markets. The Series B funding is expected to accelerate clinical development and advance the company's lead programs toward key regulatory milestones.
The Cambridge-based biotechnology firm specializes in in vivo immune programming, a therapeutic approach that distinguishes itself from conventional CAR-T cell therapies. CREATE's proprietary mRNA-lipid nanoparticle (mRNA-LNP) platform enables direct engineering of immune cell populations—specifically T cells, natural killer cells, and myeloid cells—within the patient's body rather than through ex vivo manufacturing and reinfusion. This approach aims to address scalability and cost challenges that have constrained the broader CAR-T market, while enabling repeat-dosing protocols that traditional cell therapies cannot support.
The company's clinical pipeline encompasses in vivo CAR therapies targeting both autoimmune diseases and cancer indications. This dual-indication strategy expands CREATE's addressable market beyond oncology, which has dominated CAR-T development to date, and offers investors exposure to two substantial therapeutic markets. The Series B funding is expected to accelerate clinical development and advance the company's lead programs toward key regulatory milestones.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.